CYREN (NASDAQ:CYRN) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $7.60 million which missed the analyst consensus estimate of $7.80 million by 2.56 percent. This is a 17.22 percent decrease over sales of $9.18 million the same period last year.
Canaccord Genuity Initiates Coverage On Nuvei with Buy Rating, Announces Price Target of $105
Canaccord Genuity analyst Joseph Vafi initiates coverage on Nuvei (OTC:NUVCF) with a Buy rating and announces Price Target of $105.
